IRIDEX Corp Faces Nasdaq Delisting Warning
Ticker: IRIX · Form: 8-K · Filed: Jul 3, 2024 · CIK: 1006045
| Field | Detail |
|---|---|
| Company | Iridex Corp (IRIX) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $50,000,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: listing-rule-violation, delisting-risk, nasdaq
TL;DR
IRIDEX got a Nasdaq delisting warning, needs to fix it by Dec 23 or might get moved to a lower market or kicked off entirely.
AI Summary
IRIDEX CORP announced on June 27, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has until December 23, 2024, to regain compliance. Failure to do so could result in the transfer of its listing to the Nasdaq Capital Market or delisting.
Why It Matters
This filing signals potential delisting from the Nasdaq, which could negatively impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: medium — The company is at risk of being delisted from the Nasdaq, which could significantly impact its stock value and trading.
Key Numbers
- December 23, 2024 — Compliance Deadline (The date by which IRIDEX must regain compliance with Nasdaq listing rules.)
Key Players & Entities
- IRIDEX CORP (company) — Registrant
- Nasdaq Stock Market (company) — Exchange where IRIDEX is listed
- December 23, 2024 (date) — Deadline for IRIDEX to regain compliance
- Nasdaq Capital Market (company) — Potential alternative listing market
FAQ
What specific Nasdaq listing rule did IRIDEX CORP fail to meet?
The filing does not specify the exact Nasdaq listing rule that IRIDEX CORP failed to meet, only that it received a notice of non-compliance.
What are the potential consequences if IRIDEX CORP does not regain compliance?
If IRIDEX CORP does not regain compliance by December 23, 2024, its securities may be transferred to the Nasdaq Capital Market or delisted from the Nasdaq Stock Market.
What actions is IRIDEX CORP taking to address the non-compliance?
The filing does not detail the specific actions IRIDEX CORP plans to take to regain compliance, but it acknowledges receipt of the notice and the compliance period.
When did IRIDEX CORP receive the notice of non-compliance?
The report date is June 27, 2024, and the event date is also June 27, 2024, indicating the notice was likely received on or around this date.
Has IRIDEX CORP been through this situation before?
This filing does not provide historical information about previous non-compliance issues with Nasdaq.
Filing Stats: 814 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2024-07-03 16:16:00
Key Financial Figures
- $0.01 — ich Registered Common Stock, par value $0.01 per share IRIX Nasdaq Global Market
- $50,000,000 — ities ("MVLS") was below the minimum of $50,000,000 for continued listing on The Nasdaq Glo
Filing Documents
- d214644d8k.htm (8-K) — 28KB
- 0001193125-24-175053.txt ( ) — 144KB
- irix-20240627.xsd (EX-101.SCH) — 3KB
- irix-20240627_lab.xml (EX-101.LAB) — 17KB
- irix-20240627_pre.xml (EX-101.PRE) — 11KB
- d214644d8k_htm.xml (XML) — 3KB
Forward-Looking Statements, Risks and Uncertainties
Forward-Looking Statements, Risks and Uncertainties This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Privates Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding the Company's plans to transfer the listing of its common stock to The Nasdaq Capital Market. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "believe," "may," "will," "continue," "anticipate," "assume," "plans," "intends" or similar expressions and the negatives of those terms. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Investors are cautioned not to place undue reliance on the forward-looking statements. All information provided in this Current Report on Form 8-K and in the exhibits is as of the date hereof and is based on then-current expectations and the beliefs and assumptions of management. We undertake no duty to update this information unless required by law. -2- Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). -3-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRIDEX CORPORATION By: /s/ David I. Bruce David I. Bruce Chief Executive Officer Date: July 3, 2024 -4-